ETFs & MarketsFreeFDA Draft Guidance Could Boost Gene Therapy ETFs
Draft guidance released by the U.S. Food and Drug Administration (FDA) could significantly streamline the development process for gene therapy treatments. This development may lead to increased investment activity in the biotechnology sector, particularly impacting ETFs focused on gene therapy.